Ken is a graduate from UC Berkeley where he received a BA in Biology with a emphasis in Cellular Biology. Ken started his career in the SF Bay Area where he worked for a small biotech firm named Chiron Corp, which was later acquired by Novartis Corp. At Chiron, Ken’s work focused on producing human Growth Factors in yeast for research uses and commercial production. At Novartis, Ken supported small-molecule drug discovery in many disease areas, but focused on Oncology projects. Ken has worked on several multidisciplinary projects that developed novels drug therapeutics that are currently in human clinical trials. These projects include MAPK-, and PI3K-pathway inhibitors for the treatment of cancer. “I’m excited to join cc-TDI’s vibrant and talented research community and hope to contribute to meeting our shared mission.”
Megan M. Cleary, BS
Senior Research Scientist